Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancerMyrto Moutafi, David L. Rimm, Charles T. Robbins et al.|Laboratory Investigation|2022Cited by 141
Discovery of Biomarkers of Resistance to Immune Checkpoint Blockade in NSCLC Using High-Plex Digital Spatial ProfilingMyrto Moutafi, David L. Rimm, Sandra Martínez-Morilla et al.|Journal of Thoracic Oncology|2022Cited by 40
Objective assessment of tumor infiltrating lymphocytes as a prognostic marker in melanoma using machine learning algorithmsThazin Nwe Aung, David L. Rimm, Saba Shafi et al.|EBioMedicine|2022Cited by 33
Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck CancerMyrto Moutafi, Amanda Psyrri, Georgia-Angeliki Koliou et al.|Cancer Research Communications|2023Cited by 19
Quantitative assessment of Siglec-15 expression in lung, breast, head, and neck squamous cell carcinoma and bladder cancerSaba Shafi, David L. Rimm, Thazin Nwe Aung et al.|Laboratory Investigation|2022Cited by 17